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various cancer subtypes.
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Chemical perturbation screens offer the possibility
to identify actionable sets of cancer-specific vulner-
abilities. However, most inhibitors of kinases or
other cancer targets result in polypharmacological
effects, which complicate the identification of target
dependencies directly from the drug-response
phenotypes. In this study, we developed a chemical
systems biology approach that integrates compre-
hensive drug sensitivity and selectivity profiling to
provide functional insights into both single and
multi-target oncogenic signal addictions. When
applied to 21 breast cancer cell lines, perturbed
with 40 kinase inhibitors, the subtype-specific addic-
tion patterns clustered in agreement with patient-
derived subtypes, while showing considerable
variability between the heterogeneous breast can-
cers. Experimental validation of the top predictions
revealed a number of co-dependencies between
kinase targets that led to unexpected synergistic
combinations between their inhibitors, such as dasa-
tinib and axitinib in the triple-negative basal-like
HCC1937 cell line.
INTRODUCTION
Successful examples of molecularly targeted anticancer drug
treatments exist only for a few cancer types that are driven by
druggable oncoproteins (Huang et al., 2014). Cancer sequencing
efforts have revealed that individual driver mutations may target
multiple signaling pathways, and each cancer patient may
exhibit a unique combination of mutations that are sufficient to
perturb these pathways (Vandin et al., 2012). This extensive
mutational heterogeneity poses increasing challenges for the
current target-based drug development and repurposing ap-
proaches that try to connect recurrent genomic alterations to ac-
quired cellular vulnerabilities (Garraway and Lander, 2013).
Importantly, evenwhen the critical driver genes can be identified,
these often turn out to be clinically not actionable (i.e. there is no
targeting drug available for clinical use) or pharmacologically
‘‘undruggable’’ (i.e. it is impossible to develop a drug against1144 Chemistry & Biology 22, 1144–1155, August 20, 2015 ª2015 Elthe gene product or its variant). Furthermore, genes that are
not altered at the sequence level may also play an essential
role in the disease progression, hence providing additional ther-
apeutic opportunities (Pe’er and Hacohen, 2011). For instance,
cancer sequencing studies have not found frequent mutations
in protein kinases, despite the known addiction of many cancer
cells to kinase signaling (Torkamani et al., 2009; Tyner et al.,
2013). Therefore, complementary strategies are needed to
pinpoint the functional consequences of perturbations, which
may help to prioritize the most potent and clinically actionable
drugs and their target combinations for each individual patient.
Pharmacological perturbation screens using broadly targeted
chemical libraries of bioactive small molecules enable system-
atic and direct phenotypic assays for functional investigation of
the druggable vulnerabilities in individual cancer cell types or pa-
tient-derived samples (Heiser et al., 2012; Pemovska et al., 2013,
2015). However, most chemical inhibitors of kinases and other
common cancer targets are relatively non-specific, leading to a
number of ‘‘off-target’’ effects that may either cause adverse
side effects or improve the therapeutic response (Xie et al.,
2012). Such polypharmacological effects complicate the identi-
fication of signal addictions directly from the drug-response phe-
notypes. Furthermore, the exponentially increasing number of
possible drug-target combinations is beyond the experimental
and financial capacity of even automated high-throughput
screening technologies, and translates into a need for integrated
experimental-computational approaches that enable deconvo-
luting the underlying signaling cascades behind individual
drug-response profiles. Network-based strategies can naturally
take into account the complex interactions between drugs and
their cellular targets, and so-called network pharmacology ap-
proaches are increasingly being developed for many applica-
tions (Hopkins, 2008; Tang and Aittokallio, 2014; Zhao and Iyen-
gar, 2012). However, systematic approaches that make use of
comprehensive drug response profiling to reveal druggable de-
pendencies in individual cancer samples have remained rare (Ty-
ner et al., 2013).
In the present work we developed and tested a network phar-
macology approach, which integrates cell-based drug sensitivity
profiling with biochemical target selectivity information for sys-
tematic identification of druggable molecular vulnerabilities in
given cancer cells. This approach enables the identification of
both individual kinase target addictions (i.e. essential kinase sig-
nals) and combinatorial co-dependencies between kinase pairs
and synthetic lethal type interactions (i.e. co-essential kinasesevier Ltd All rights reserved
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Figure 1. Schematic Illustration of the
Single and Combinatorial Kinase Inhibition
Sensitivity Score
(A) Left: Single kinase inhibition sensitivity score
(KISS) ranks each kinase (k) in the context of a
given drug-target network based on the average
drug response (DR) over the subset of its potent
inhibitors (n). Single KISS enables one to prioritize
pharmacologically actionable kinase signal ad-
dictions in individual cancer cell samples for
experimental validation. Right: The KISS concept
was extended to ranking kinase pairs (ka, kb) based
on their average combinatorial effect over the
subset of inhibitors targeting both of the kinases
(m). Combinatorial KISS enables one to identify a
synthetic lethal type of target pairs, whichmay lead
to synergistic drug combinations between their
inhibitors (see B for the rationale of the filtering
step). Experimental testing of the combinatorial
KISS predictions was carried out here by simulta-
neous siRNA-based silencing of the highly ranked
kinase pairs and by combinations of drugs that
show most potency as inhibitors of ka and kb.
(B) Relationships between the single and combi-
natorial KISS defined using set-theoretic opera-
tions among the set of inhibitors. Using this nota-
tion, the cardinality of the set A is n and the
cardinality of the intersection between A and B is
m. The complement score (cs) of ka or kb is defined
as the average response over the inhibitors that
belong to the difference between sets A and B or B
and A, respectively (the shaded portions).signals). The integrated approachmakes use of the polypharma-
cological effects of compounds in terms of utilizing both their
unique and shared on- and off-targets in the deconvolution of
the underlying kinase signaling pathways. As a proof-of-principle
case study, we used triple-negative breast cancer (TNBC), a
highly aggressive and heterogeneous class of breast cancer,
with currently no targeted treatments available, mainly due to
the lack of known single drivers (Grigoriadis et al., 2012). There-
fore, TNBC serves as a highly challenging disease model to
identify druggable molecular addictions and combinatorial
co-dependencies in a cell type-specific manner. Although we
focused here on breast cancer cell lines and kinase inhibitors,
the experimental-computational approach is also widely appli-Chemistry & Biology 22, 1144–1155, August 20, 2015cable to other target families and cancer
types, as well as to patient-derived cell
samples in clinical applications.
RESULTS
Kinase Inhibition Sensitivity Score
for Predicting Single and
Combinatorial Molecular
Addictions
We implemented an experimental-com-
putational target deconvolution ap-
proach, dubbed the kinase inhibition
sensitivity score (KISS), which maps ki-
nase inhibitor sensitivity and selectivityprofiles onto a drug-target network (Figure 1A). Our computa-
tional algorithm ranks the individual kinases according to their
likelihood of being essential for the growth of a particular cancer
cell (Pemovska et al., 2013; Yadav et al., 2014). The basic
assumption behind the KISS addiction scoring model is that
the increased sensitivity of a cancer cell to a given drug com-
pound implies that its molecular targets are jointly and/or individ-
ually essential for the survival of the cancer cell, whereas drug
treatment insensitivity implies that the particular cell is not ad-
dicted to the targets of the particular compound.
Formally, KISS for a given kinase target is calculated as the
averagedrug responseover the subset of its potent inhibitors (Fig-
ure 1A, left). We extended this concept also to kinase target pairs,ª2015 Elsevier Ltd All rights reserved 1145
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Figure 2. KISS and Quantitative Drug-
Target Mappings Improve the Identification
of Known Breast Cancer Drivers
(A) Systematic evaluation of cancer addiction
identification approaches, each based on a com-
bination of a deconvolution method, a type of
drug-target mapping, and a drug-response metric
as input.
(B) Drug sensitivity score (DSS, Table S1) is based
on the integration of the area under the dose-
response curve (Yadav et al., 2014), and combines
several response parameters such as relative half-
maximal inhibitory concentration (IC50).
(C) The number of inhibitors that target a given
number of kinases among the tested drug collec-
tion of 40 inhibitors and 205 kinase targets.
Dissociation constant (Kd) values (Davis et al.,
2011) were used to define here the quantitative
drug-target (qDT) mappings according to expert
filtering (Table S3). The solid curve corresponds to
a power function.
(D) Ordering of the 31 tested combinations ac-
cording to the median rank of known drivers used
as positive controls. Color coding of the KISS-
based combinations corresponds to the different
types of drug-target mappings (see A). NA marks
those combinations in which the driver was absent
in the particular type of drug-target interaction
data. Red font indicates combinations based on
DSS. Table S4 gives the full results from each
combination.by means of combinatorial KISS, which enables the prediction of
such kinase pairs whose simultaneous inhibition leads to
increasedcell death (Figure1A, right). To focuson the synthetic le-
thal type interactions,we retainedonly those target pairs forwhich
the combinatorial effect wasmarkedly higher than that originating
fromthe inhibitors targetingonly oneof thekinases (Figure1B; see
also Experimental Procedures). It was hypothesized that tracing
back the inhibitors behind such co-essential target pairs could
lead to unbiased prediction of synergistic drug combinations.
KISS Enabled the Prediction of Context-Specific Drivers
in Heterogeneous Breast Cancer Cells
In this proof-of-principle study, we examined the sensitivity of
21 breast cancer cell lines to a panel of anticancer com-1146 Chemistry & Biology 22, 1144–1155, August 20, 2015 ª2015 Elsevier Ltd All rights resepounds using the drug sensitivity and
resistance testing platform (Pemovska
et al., 2013) (Table S1). Specifically, 15
of the cell lines represented TNBC sub-
types, three were ER and PR positive,
two were Her2 positive, and one was
Her2, ER, and PR positive (Table S2).
To evaluate the relative performance of
KISS across these breast cancer cell
lines, we ranked the kinase targets
based on a representative set of
computational target deconvolution
methods (Figure 2A): Tyner’s score (Ty-
ner et al., 2013), Fisher’s test (Wei
et al., 2012), and Spearman’s correla-tion (Tran et al., 2014) (see Experimental Procedures). Drug
response was quantified either as half-maximal inhibitory con-
centration (IC50) or by using the drug sensitivity score (DSS)
(Yadav et al., 2014) (Figure 2B). Quantitative drug-target selec-
tivity profiles were available from a biochemical assay (Davis
et al., 2011) for 40 kinase inhibitors in our compound collec-
tion (Table S3), whose target distribution followed the power
function (Figure 2C). We also tested whether targets extracted
from public drug databases (KEGG, Therapeutic Target Data-
base, and DrugBank) could improve the identification of kinase
addictions (Figure 2A). Each of these combinations of a target
deconvolution method, a drug-target mapping, and a drug
response metric gave rise to a separate ranking of kinase tar-
gets (Table S4).rved
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Figure 3. KISS-Based Clustering Reveals TNBC Subgroups in Agreement with Patient-Based Subtypes
(A) Unsupervised cluster solutions based on KISS (left) and DSS (right) were compared with the five subgroups established in TNBC patient tumors based on their
transcriptomic profiling: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), and mesenchymal stem-like (MSL). For each of these
patient-derived subgroups, a set of representative TNBC cell lines was previously determined (Lehmann et al., 2011). The cell lines overlapping with our cell line
collection were used here in the cluster evaluation (Table S2 provides the characterization of all cell lines). The luminal androgen receptor (LAR) subgroup was
excluded due to the lack of androgen receptor antagonists in our kinase inhibitor panel. See also Figure S1 for KISS-based clustering of all tested cell lines.
(B) Adjusted R and index for the quantitative assessment of agreement between the KISS- and DSS-based cluster solutions with the patient-derived TNBC
subtypes.The systematic evaluations demonstrated the improved ability
of the KISS-based combinations to predict known kinase drivers
of breast cancer cell lines (ERBB2 in BT474 and SKBR3, BRAF in
DU4475 aswell as PIK3CA/PI3Ka inMCF7 and T47D; Figure 2D).
Strikingly, all of the top four rankings of these positive controls
were based on KISS and DSS, and 11 out of 12 top rankings
were based on the DSS, indicating that the DSS metric provides
an improved means beyond the standard IC50 to elucidate can-
cer cell addictions. As was expected, the differential version of
DSS improved the prediction results when the aim was to find
selective addictions that are specific to a given cancer cell. How-
ever, merging unary drug-target interactions with quantitative
target selectivity profiles did not lead to improvements in the pre-
dictive accuracy, suggesting that taking into account negative
drug-target interactions has an important role in the driver pre-
dictions. The KISS version that utilizes differential DSS and
quantitative drug-target profiles turned out to be the overall
best combination across all the tested cell lines and their known
drivers (Figure 2D). This version was therefore used in the further
evaluations and applications of the KISS approach.
KISS-Based Cancer Cell Clustering Closely Resembled
Patient-Derived TNBC Subtypes
Unsupervised clustering of the breast cancer cell lines based on
their KISS profiles revealed three major clusters with distinct
kinase signal addictions (Figure 3A). To test whether the KISS-
based functional clustering could identify breast cancer sub-
types similar to those observed in patient tumors, we compared
the clusters derived from the KISS profiles with the classification
obtained using genome-wide molecular profiles from 587 TNBC
cases (Lehmann et al., 2011). It was found that the KISS-based
clustering agreed better with the patient-derived TNBC sub-
types, compared with that using the drug response profile alone
(Figure 3B).Chemistry & Biology 22, 1144–Notably, the KISS profiles of MDA-MB-436 and DU-4475 did
not cluster together with any other TNBC cell lines (Figure 3A).
This is because the experimentally validated top kinase predic-
tions in MDA-MD-436, including GLK/MAP4K3, KHS/MAP4K5,
TYK1/LTK, RON, MET, and IRAK4 (Figure 4), were distinct
from the set of significant addiction scores in the other mesen-
chymal-like cell lines (p < 0.05, permutation-based test). Simi-
larly, DU-4475, which represents the immunomodulatory sub-
type (Lehmann et al., 2011), did not cluster together with the
other basal-like cell lines due to its validated addictions to
RAF family and SRMS kinases (Figure 4). It also had common
predicted drivers with mesenchymal-like CAL51 and Hs578T
cell lines, including CAMKs, GRKs, and PKNs, which had very
low KISS values in all the basal-like cell lines (Table S4; Fig-
ure S1). These results indicate that the KISS profiles provide
additional information beyond the established breast cancer
cell types.
Predicted Kinase Addiction Patterns Showed Variability
between and within Established Cell Types
In addition to the known oncogenic drivers, the KISS-based
rankings suggested novel cell line-specific druggable addic-
tions. To experimentally test a set of novel addiction predictions,
we initially focused on the HDQP1 cell line, which was predicted
to be strongly addicted to CSK, BMX, HCK, and IRAK and to
ephrin receptor tyrosine kinases (Figure 4; Table S4). Since its
addiction profiles partially overlapped with those of CAL51 and
Hs578T, we tested a selection of top addiction predictions in
these three TNBC cell lines using both siRNA-based kinase
knockdowns and an independent set of compounds that inhibit
the predicted kinases but were not used in the model construc-
tion or KISS predictions (Figure 4). In general, we were able to
confirm a number of the predicted hits by an independent com-
pound and/or siRNA validation assays (Figure 4; Table S5).1155, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1147
Figure 4. Unique and Shared Kinase Addiction Patterns among the Heterogeneous Breast Cancer Cell Lines
The kinase addiction network was constructed among the statistically significant KISS values in separate cell lines (p < 0.06, permutation test). The node color
represents the type of experimental evaluation performed for the particular kinase prediction in a given cell line. The edge color represents the result of the
validation experiment(s) utilizing either independent drugs (i.e. targeted kinase inhibitors not among the FIMM compound panel) and/or siRNA-based kinase
knockdown (i.e. silencing of the predicted kinase target using three siRNAs per kinase in three replicates). Kinases that are known to be drivers of the cell lines are
marked with a red node border and a green kinase label. The independent siRNA and drug validations were considered positive if the average siRNA inhibition
from the two most effective siRNA sequences was above 35% and the drug sensitivity score was above 7, respectively. Table S5 gives the full validation data.Taking CAL51 as an example TNBC cell line, our experimental
validations confirmed the importance of multiple AMP-activated
protein kinase-related kinases, such as ARK5 (NUAK1), SNARK
(NUAK2), andMARK3 (Figure 4; Table S5). In addition, CAMK2A,
PKN1, RIOK2, PRP4, and SRPK3were experimentally confirmed
by growth inhibition following their knockdown by siRNAs. Both
the siRNA and compound perturbation results supported the es-
sentiality of ARK5, SNARK, and MST1, as well as dasatinib tar-
gets EPHA5, EPHB4, HCK, and TXK. Notably, many of the
KISS-predicted addictions have been previously implicated in
cancers (Table S5). The number of kinase predictions confirmed
either in our validation experiments or in other studies provides
proof-of-concept support for the approach and its applicability
to finding novel cancer cell-specific kinase addictions.
Predicted Kinases and Their Interaction Partners
Formed Cell Type-Specific Signal Addiction Networks
The top KISS predictions turned out to form well-connected
signaling networks consisting of both physical and functional in-1148 Chemistry & Biology 22, 1144–1155, August 20, 2015 ª2015 Elteractions, suggesting that the individually most essential kinase
targets play a role in shared biological processes. Focusing
again on CAL51, we took a closer look at the interaction partners
in the CAL51-centered network (Figure 5). The network analysis
revealed that the KISS-predicted kinases formed a connected
subnetwork with SYK as its main hub (Figure 5A; Table S6).
SYK has been shown to regulate proliferation as a tumor sup-
pressor, and inhibits breast cancer cell growth (Moroni et al.,
2004; Sung et al., 2009). Furthermore, its early loss during pro-
gression of the disease was linked to poor prognosis andmetas-
tasis (Blancato et al., 2014; Toyama et al., 2003). Interestingly
CAL51, a metastatic breast cancer cell line, had the lowest
expression of SYK among all the tested cell lines (Barretina
et al., 2012), raising the possibility that the observed growth inhi-
bition upon targeting some of its interaction partners might be
mediated by its reactivation. Importantly, siRNA knockdown of
a number of significant kinase addiction predictions in the
SYK-interactome showed marked growth inhibition (Figure 5B).
The CAL51 addiction network was also highly enriched in severalsevier Ltd All rights reserved
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Figure 5. Integrative Network Analysis
among the Strongest Kinase Addiction Pre-
dictions in CAL51
(A) The signal addiction network based on inter-
actome analysis of the top predictions in CAL51 is
highly connected with SYK as its most promiscu-
ous hub. The high-confidence physical in-
teractions occurring in breast neoplasm were ex-
tracted from the HIPPIE database for significant
kinase addictions (p < 0.06). The GeneMania
database was used to map the genetic in-
teractions between the top predictions as well as
pathway interactions involving the proteins in the
network.
(B) Top kinase predictions validated by siRNA
knockdown. Only hits with at least 35% average
inhibition over the three replicates of the top two
siRNA sequences are shown here, together with
their error bars (SEM). Red bars represent the
siRNA results in the CAL51 cell line, whereas green
bars represent negative control cell lines, in which
the KISS addiction prediction was insignificant
(HDQP1 and HCC1937).
(C) Selected gene ontology biological processes
that were highly enriched in the CAL51 signal
addiction network (p < 0.005). The number of
genes associated with a given GO term in the
CAL51 network is marked beside the bars.
See Figure S2 for other cell line-specific networks
and Table S6 for details of the interactions.cancer-related gene ontology (GO) processes (Figure 5C; Table
S6). An enrichment of several immune function and inflamma-
tion-related processes was also seen in the MDA-MB-436 and
HDQP1 TNBC addiction networks (Figure S4). Notably, the toll-
like receptor signaling pathway was among those enriched,
consistent with previous studies showing the importance of
this signaling pathway in breast tumor cell invasion, survival,
and metastasis (Gonzalez-Reyes et al., 2010; Merrell et al.,
2006; Yang et al., 2010).
KISS-Predicted Kinase Addictions Showed Consistency
between Two Independent Compound Collections
We also evaluated the consistency of the kinase addiction
scoring using a distinct panel of 295 kinase inhibitors from Glax-
oSmithKline (GSK) (Knapp et al., 2013), which contains 87
shared kinase targets with our collection of 40 compounds (Fig-
ure 6A). Rankings of the shared kinases according to their KISSChemistry & Biology 22, 1144–1155, August 20, 2015 ªvalues, which were calculated based on
drug responses in the two compound
panels, revealed a significant association
when applied to HER2-positive and ER-
negative cell lines (Figure 6B; p < 0.05,
Fisher’s exact test) and an overlapping
set of top functional addictions (Table
S7). The significant overlap in the KISS
profiles between these two distinct sets
of kinase inhibitors is especially striking
given the differences in their target selec-
tivity profiling: the Institute for Molecular
Medicine Finland (FIMM) compound tar-gets were extracted from the competition binding assays (Davis
et al., 2011), whereby dissociation constant (Kd) levels were esti-
mated based on serial dilutions of a test compound across
several concentrations, whereas the target annotations for the
GSK compoundswere extracted from two-dose testing in kinase
assays (Knapp et al., 2013). This indicates that the kinase addic-
tion predictions were not merely due to the compounds covered
by our kinase inhibitor panel, but consistent addiction scores
were obtained also when using an independent set of drug
probes targeting the overlapping portion of the kinase space.
Combinatorial KISS Revealed Synergistic Drug
Interactions and Co-essential Kinase Pairs
Sincemost cancer cells are dependent onmultiple driver signals,
we extended the KISS approach to also elucidate combinatorial
molecular addictions, so-called druggable co-dependencies, in
each cancer cell type individually. To predict synthetic lethal2015 Elsevier Ltd All rights reserved 1149
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Figure 6. Comparison of the Top-Ranked Kinase Addictions be-
tween Two Independent Compound Collections
(A) Overlap of the kinase inhibitors and their kinase targets between the GSK
and FIMM compound sets.
(B) Correlation of the KISS-based kinase rankings in two representative cell
lines. KISS values were calculated for the 87 common kinase targets in the two
non-overlapping drug sets (FIMM and GSK drug collections, Table S7). The
resulting rankings revealed a common set of top signal addictions and were
significantly correlated (p < 0.05, Fisher’s exact test). Red and green lines
indicate the average KISS level in the FIMM and GSK rankings, respectively,
which were used as cut-off values in the contingency tables of the Fisher exact
test for the association between the two rankings.type interactions between kinase pairs, whose simultaneous in-
hibition leads to increased cancer cell death compared with the
inhibition of each kinase individually, we first calculated the
combinatorial KISS for all kinase target pairs in a given cell
line, and then compared the predicted combination effect with
those effects originating from inhibiting the single kinases alone
(Figure 1A, right). We focused on those kinase pairs for which the
combinatorial KISS was positive and exceeded the complement
scores (here T = 4; see Figure 1B); these pairs were then ranked
by the magnitude of their combinatorial KISS (Figure 7; Table
S8). For the proof-of-concept validations, we chose the
HCC1937 TNBC cell line, since it does not harbor any strong sin-
gle driver addictions, thereby being a good model system for
testing novel combinatorial treatment alternatives.
We hypothesized that the compounds which are the strongest
non-common inhibitors of each individual kinase in the highly
ranked kinase pairs should show a degree of synergism. To
test this hypothesis, we paired the most potent inhibitors of the
single kinases (Figure 7); these compound pairs were experi-
mentally tested for their combined efficacy in the selected cell
line in increasing inhibitor concentrations. Since some of the ki-
nases were targeted by only a single compound, which some-
times was shared among several selected kinase targets, there
were a number of kinase pairs (and thus compound pairs) with
the same combinatorial KISS value, originating from their com-
mon inhibitors (the colored panels in Figure 7). Notably, however,
we confirmed experimentally that at least one compound pair in
each such combinatorial KISS class resulted in a synergistic
phenotype (the pairs in boldface in Figure 7). For each of these1150 Chemistry & Biology 22, 1144–1155, August 20, 2015 ª2015 Elsynergistic combinations of nintedanib with enzastaurin, bosuti-
nib with pazopanib or foretinib, and dasatinib with axitinib, the
observed joint growth inhibition was markedly greater than the
expected effect based on the Bliss independence model (Fig-
ures 8A and 8B), and greater than the combination effect
observed in the self-crosses of these single agents (Table S9).
We further tested the predicted co-essential kinase pairs that
led to synergistic compound combinations using siRNA-medi-
ated target knockdown. We discovered that the majority of the
selected kinase pairs (9 of 11 validated pairs, Figure 7) showed
a co-essential phenotype, defined as higher combinatorial
growth inhibition effect than that caused by each individual ki-
nase when silenced alone. Strikingly, in seven out of these nine
pairs, the combinatorial silencing effect was higher than 2-fold
their expected effect (Figure 8C; Table S10). In particular, the ki-
nase pairs predicted to underlie the synergistic compound ef-
fects (EPHB6 with AURKC, GCK with TAOK3 or CDK7, and
GSK3b with PCTK1) were also shown to be co-essential. Taken
together, these results suggest that the combinatorial KISS
approach can identify unexpected synergistic interactions be-
tween compounds, which are often due to synthetic lethal type
interactions between the kinase targets of the individual inhibi-
tors that target distinct pathways (Table S11). This model hence
explains the synergistic inhibition effect via a specific co-depen-
dency pattern, in which the cancer cell is addicted to a number of
kinase signals, each of which needs to be inhibited for maximal
cancer cell killing.
DISCUSSION
We recently demonstrated how comprehensive testing of drug
sensitivities in cells from leukemia patients may lead to unpre-
dictable, clinically significant drug-repositioning opportunities,
as well as to hypotheses about potential kinase-driven signaling
networks to which the patient-derived cells may be addicted
(Pemovska et al., 2013, 2015; Yadav et al., 2014). Once carefully
tested, such network-based approaches could facilitate clinical
decision making by means of mapping the key oncogenic sig-
nals underlying both the initial treatment sensitivity and acquired
resistance during the disease evolution.
In the present study, we developed and tested a systematic
chemical systems biology tool to explore druggable cancer ad-
dictions, both single kinase targets and their synthetic lethal
type combinations, through integrating functional perturbation
profiles from cell-based drug sensitivity assays and drug-target
information from biochemical target selectivity assays. In an
application to 40 kinase inhibitors, which span the target network
among 205 kinases, we demonstrated how this integrated
approach enabled us to classify selective kinase addiction pat-
terns across heterogeneous TNBC cell lines in agreement with
their clinical subtypes while showing considerable variability be-
tween the heterogeneous breast cancer cells, hence pinpointing
putative mechanisms of drug sensitivity and resistance in a
context-specific manner. Using known oncogenic drivers, such
as ERBB2/HER2, BRAF, and PIK3CA, we showed that our ki-
nase addiction score improves the ranking of the molecular ad-
dictions in a subset of breast cancers known to be driven by
these kinases. Our unsupervised approach not only identified
known breast cancer drivers in a totally unbiased manner, butsevier Ltd All rights reserved
Figure 7. Combinatorial KISS Results in the
HCC-1937 Cell Line
The combinatorial KISS was calculated for a
particular kinase pair (k1, k2) by averaging the drug
response (DSS) over their common inhibitors that
target both k1 and k2 (see Figure 1). The different
background color panels indicate the sets of
kinases (and compound pairs), which were indis-
tinguishable by the current compound-target
mappings. Boldface font indicates those com-
pound and kinase pairs for which we have exper-
imental support from compound and/or siRNA
testing for being either synergistic or co-essential,
respectively, and an asterisk indicates that the ki-
nase pairs that were not experimentally tested in
the present study.also predicted a number of novel druggable addictions,
including SNARK, ARK5, CAMK2A, SRMS, and PKN1. Experi-
mental validations using both compound and siRNA combina-
tions demonstrated that the model also successfully predicted
a number of co-essential kinase pairs and synergistic kinase in-
hibitor combinations in the basal-like HCC1937 TNBC cell line,
such as dasatinib with axitinib, enzastaurin with nintedanib, as
well as bosutinib with pazopanib or foretinib, in which the com-
bined inhibition power could not be explained by the efficacy
of the two single compounds when used alone. Even though
several of these compounds are currently not yet approved, their
overlapping polypharmacology helped the network model to
identify unexpected synergistic combinations regardless of their
approval status (Table S1). Although we sometimes observed
synergies at rather high concentrations, which may not be clini-
cally feasible, the current proof-of-concept results could be
further improved with an increasing knowledge of the drug-
target selectivity. The present study focused on kinase inhibitors,
due to their importance in anticancer drug development (Apsel
et al., 2008; Fedorov et al., 2010) and the availability of compre-
hensive target selectivity profiles (Davis et al., 2011), but the
chemical systems biology approach is applicable to any sets
of compounds with known and partly overlapping target profiles.
Perhaps the biggest limitation of any target deconvolution
method comes from the lack of comprehensive and accurate
target annotations for many targeted compounds. Conse-
quently, multiple kinases tended to obtain the same KISS value
(e.g. all those targets having the same set of inhibitors in a given
cell line). Experimental testing of these predictions is essential to
discriminate the potential false positives. Similarly, since the joint
inhibition of kinase pairs by the same set of drugs results in equal
scoring from the combinatorial KISS, the compound combina-
tion rankings may also have ties (i.e. multiple kinase pairs ex-
plaining the efficacy of their common set of inhibitors). In our
experimental validations, we were able to confirm one synergis-
tic compound pair in each of the combinatorial KISS classes
(Figure 7; Figures 8A and 8B). However, it is likely that anChemistry & Biology 22, 1144–1155, August 20, 2015increased number of kinase inhibitors
with overlapping target spaces will lead
to more high-resolution predictions in
the future. Furthermore, experimental is-
sues may lead to some false-negativefindings, i.e. lowly ranked kinases that are important for the can-
cer cell survival, for instance, due to the relatively short assess-
ment time of drug sensitivity (in this case, 3 days), which may be
insufficient to affect the viability readout. In addition, an efflux
transporter effect may mask sensitivity to a kinase inhibitor,
and thereby the addiction to the kinase function could remain un-
detected in compound phenotypic testing. However, our siRNA
knockdown validation experiments gave complementary sup-
port for the essentiality of the predicted kinases. As a future
development, it might be useful to combine the chemical and
RNAi-based perturbation experiments with genomic analyses
to provide improved identification of molecular addictions and
co-dependencies, along the lines suggested in recent integrative
studies (Gatza et al., 2014; Sundaramurthy et al., 2014; Vizea-
coumar et al., 2013).
In summary, our integrated phenotype-based strategy pro-
vides complementary information compared with cancer
sequencing efforts, which have their limitations in translating
the genomic aberration into clinically actionable therapeutic
strategies. For instance, even when causal aberrations can be
identified, these are often pharmaceutically non-targetable,
and even if druggable genetic alterations can be found, targeting
them in the clinic often proves ineffective because of redundant
activated driver signals or adaptive compensatory signaling.
Compared with the genomic-based approaches (Aksoy et al.,
2014; Tan et al., 2012), our functional approach does not require
any background knowledge of the genetic alterations or other
molecular biomarkers to elucidate potential therapeutic strate-
gies. This may make it more straightforward to translate the
most actionable predictions into a clinical setup, based solely
on the ex vivo response of patient cells to a collection of drugs
with known target annotations. The synergistic effects of drug
combinations predicted by the combinatorial KISS suggest
that this approach can identify new unexpected treatment stra-
tegies that modulate multiple, redundant, or compensatory
signaling pathways. Finally, our results warrant the development
of improved inhibitors with higher dual potency and selectivityª2015 Elsevier Ltd All rights reserved 1151
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Figure 8. Combinatorial KISS Predicts
Synergistic Compound Combinations and
Co-essential Kinase Pairs
(A) Dose-response curves for the synergistic inhibi-
tor effects on cell viability in HCC1937. Each com-
bination was tested in two to four replicates. Points
and error bars represent the mean and its SE,
respectively, and the solid curve is the logistic
function fit. The expected combinatorial effects were
calculated based on the Bliss independence model
(Bliss, 1956).
(B) Examples of the full dose-response matrices
showing the effects of the synergistic compound
combinations on the cell viability (left) and their Bliss
excess scores (right).
(C) Effects of single and combinatorial siRNA
knockdowns of the top kinase pairs on HCC-1937
cell viability. Three siRNAs per gene were tested
both in a 3 3 3 matrix format (combination effects)
and alone (single effects) in three replicates. Bars
and error bars represent percent inhibition and SE
after single and combinatorial siRNA knockdown of
the selected pairs. For scoring of co-essentiality, the
maximum single effect was used as the baseline
comparison level for the combination effect.
Tables S8, S9, S10, and S11 provide the full data.
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toward the top target pairs, which could further improve the
treatment efficacy as shown earlier (Dar et al., 2012).We envision
that iterative experimental drug sensitivity testing followed by
combinatorial KISS analyses and chemical optimization could
offer a powerful means for phenotype-driven development of
new, highly disease subtype-selective drug leads.
SIGNIFICANCE
This proof-of-principle study demonstrates how integration
of kinase inhibitor perturbation screens with computational
target deconvolution approaches offers possibilities to
elucidate both mono- and multi-targeted molecular addic-
tions in individual cancer cells. As broad-scale drug sensi-
tivity testing is becoming a commonly used approach to
functionally profile both cancer cell lines and patient-
derived cancer cells, our integrated platform can greatly
benefit many chemical, biological, and clinical applications.
Integration of comprehensive chemical screening and target
selectivity profiling provides improved understanding of the
biological mechanisms behind drug sensitivity and resis-
tance in individual cancer types and patients. Experimen-
tally, our approach enables computational prediction of
synergistic target and drug pairs, which may help to priori-
tize and speed up the experimental testing of the massive
number of potential combinations. Personalized medicine
programs should also benefit from the systematic mapping
of oncogenic driver signals and pharmaceutically actionable
molecular addictions during cancer progression and
relapse, as well as from the possibility to predict next-line,
combination therapeutic opportunities that are tailored for
the individual, relapsed patient.
EXPERIMENTAL PROCEDURES
Cell Line Material
The characteristics of the breast cancer cell lines, including their vendors and
culturing conditions, are detailed in Table S2.
Drug Sensitivity Screening
The sensitivity of the 21 breast cancer cell lines to 239 anticancer compounds
was tested using the DSRT platform (Pemovska et al., 2013). Each compound
was tested in five concentrations, across a 10,000-fold range, allowing for the
establishment of dose-response curves and their subsequent quantification
by IC50 and the DSS (Yadav et al., 2014). The DSS values of the compounds
and their clinical status are provided in Table S1. Differential DSS and IC50
values were calculated using either the mean over all cell lines or the
MCF10A cell line as a control. The same protocol was used for testing the
GSK compounds in the MDA-MD-453 and SKBR3 cell lines. An independent
set of drugs used in validations of the KISS predictions was tested in selected
cell lines using eight concentrations over a 10,000-fold range (see Independent
Drug and siRNA Testing). The predicted drug synergies were tested in an 83 8
dose-matrix format (see Combinatorial Drug Synergy Testing).
Drug-Target Mappings
As a source of quantitative drug-target data, we used the biochemical compe-
tition binding study performed by Davis et al. (2011), where the Kd values for
205 non-mutated kinases were available for 40 inhibitors from our FIMM
drug collection. Drug targets were defined using drug-specific Kd thresholds
(50-fold from the strongest target of a given inhibitor or below 100 nM, which-
ever threshold came first), followed by an expert manual curation, resulting in a
quantitative drug-target dataset (qDT, Table S3).Chemistry & Biology 22, 1144–As a source of non-quantitative, unary drug-target data (uDT), we combined
kinases listed as targets in KEGG (http://www.genome.jp/kegg), the Therapeu-
tic Target Database (http://bidd.nus.edu.sg/group/cjttd), and DrugBank
(http://www.drugbank.ca). This resulted in 296 kinase targets for 142 drugs
in our FIMM drug collection (Table S3). Such unary target selectivity data
specify which kinases have been reported as targets of a given drug, but lack
the information about those not being reported as a target or not being tested.
For the GSK compounds, we used the kinase activity assay from Knapp
et al. (2013), available in ChEMBL (https://www.ebi.ac.uk/chembl/), where
the kinases were subdivided into five categories (from 0, inactive to 4, very
active), based on the inhibition of their activity at 1 and 0.1 mM concentrations
of a particular compound, according to pre-defined thresholds. Kinases clas-
sified into categories 3 and 4 were considered to be targets of the GSK com-
pounds. Kinases belonging to category 2 were considered to be targets only if
the compound had no targets in higher categories.
Kinase Addiction Predictions
To make a systematic comparison of the KISS approach with previous
methods, we ranked the kinase targets using the drug response profiles in
each cell line based on Tyner’s score (Tyner et al., 2013), Fisher’s test (Wei
et al., 2012), and Spearman’s correlation (Tran et al., 2014). In the Tyner score
method, kinases from the quantitative drug-target data for each drug were
subdivided into five tiers depending on the magnitude of their Kd or IC50 value
(Tyner et al., 2013). Each kinase was then assigned a cumulative score, result-
ing from addition of points (its effective inhibitors) and subtraction of points (its
ineffective inhibitors).
In the Fisher test method, a p value for each kinase was calculated based on
the number of its active inhibitors, active non-inhibitors, inactive inhibitors, and
inactive non-inhibitors (Wei et al., 2012). The active drugs were defined to be
among the top 20% of the most effective drugs in a given cell line. In the
Spearman correlation method, the kinases were ranked based on the correla-
tion between drug response and the kinase selectivity profile in each cell line
separately. The Fisher test and Spearman correlation-based methods were
tested with quantitative drug-target data (qDT) and two types of drug response
data (IC50 or DSS). In addition, we tested both non-differential and differential
versions of IC50 and DSS (see the explanation in Drug Sensitivity Screening).
Altogether we examined 31 technically possible combinations of the deconvo-
lution method, drug response data, and drug-target data, each resulting in a
separate ranking of kinase targets (Table S4).
Comparison of the Kinase Addiction Predictions
To evaluate the kinase target rankings resulting from the different approaches,
we extracted the ranks of known kinase drivers (ERBB2/HER2, BRAF, and
PIK3CA/PI3Ka) in seven of the cell lines as positive controls, and calculated
their median rank across these cell lines. The mutations of PIK3CA and
BRAF in breast cancer cells were extracted from the COSMIC database (as
of June 2012; http://cancer.sanger.ac.uk/). Only cell lines harboring amutation
that had an impact on the protein function were used in the evaluation. The
functional impact was assessed using the IntOGen database (as of March
2013; http://beta.intogen.org/web/cell-lines).
Statistical Significance of a KISS Value
To assess the statistical significance of an observed KISS value, we deter-
mined the empirical p values using permutations tests. More specifically, a
vector consisting of numbers of inhibitors per kinase was used to randomly
select a given number of inhibitors for each kinase, whose drug response
values in a given cell line were then averaged. In other words, the links in the
drug-target network were randomly re-ordered while preserving the overall
distribution of the number of inhibitors per kinase. The permutation procedure
was repeated, simulating at least 10,000 random KISS values in a given cell
line. The empirical p value was defined by the percentage of the permuted
KISS values above or equal to the observed one (Table S4).
Construction of Addiction Networks
The CAL51 addiction network was constructed using the high-confidence inter-
actions, both physical and associations, in breast neoplasm for the topKISSpre-
dictions from the HIPPIE database (http://cbdm.mdc-berlin.de/tools/hippie),
where only the interactors connected with at least three input proteins were1155, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1153
retained. The resulting network was further populated using pathway and ge-
netic links extracted from GeneMania (http://www.genemania.org). For visual-
ization purposes, genetic interactions with less than two proteins from the top
KISS predictions were filtered out. The network was visualized using Cyto-
scape v.3.0.1. Enrichment of GO biological processes was analyzed using
ClueGo v.2.8 (Bindea et al., 2009), with the minimum number and percentage
of genes per term being set to 4 and 2, respectively, and the Benjamini Hoch-
berg method applied as the p value correction method (Table S6).
Independent Drug and siRNA Testing
The top single KISS predictions were tested in selected cell lines using both
siRNA knockdowns and an independent set of kinase inhibitors. The predic-
tions fromMDA-MD-436 and DU4475 cell lines were tested using independent
drugs only, whereas the predictions from HDQP1, Hs578T, and CAL51 were
tested using drugs and/or siRNAs, depending on the kinase target. As addi-
tional drugswechose those that had the lowestKd values for the kinase inques-
tion (Davis et al., 2011), but were not previously tested in the FIMM drug set
used to generate the KISS predictions. These independent drugswere ordered
fromMedChemexpress and tested in the same way as described above (Drug
Sensitivity Screening). siRNA validations were performed using three siRNA
sequences per kinase individually at a concentration of 10 nM and tested in
three replicates in the cell lines predicted to be positive and negative for each
kinase addiction. The siRNAs for the kinases as well as for the positive and
negative controls were ordered from Ambion and tested using the same proto-
col as described below (siRNA Combination Testing) with 750 cells per well for
all cell lines, except for HCC1937 and BT549 whereby 500 cells per well were
used. The number of cells for platingwas determined based on the transfection
optimization experiments. Fluorescence values were converted to percent in-
hibition using positive and negative controls. The average siRNA knockdown
was calculated for each sequence based on the three replicates, and the two
highestmeanswere further averaged to result in the final siRNA inhibition score.
Kinases whose final siRNA inhibition score was R35% were considered as
positively validated. For the independent drug tests, we considered DSSR7
as an indication of a positive validation (Table S5).
Combinatorial KISS Predictions
The combinatorial KISS score was calculated for all kinase pairs that had com-
mon inhibitor(s) as well as individual inhibitors among the 40 kinase inhibitors in
common between our FIMMdrug collection and the selectivity profiling assays
(Davis et al., 2011). Kinase pairs that had no common inhibitors or no single ki-
nase inhibitors in our compound collection were excluded from the combina-
torial analysis. Next, to focus on synthetic lethal type of kinase pairs, termed
co-essential, we excluded all those pairs for which the difference between
the combinatorial KISS and the complement scores was below a selected
cut-off value (here T = 4, see Figure 1). The remaining kinase pairs were ranked
by the magnitude of their combinatorial KISS and mapped back to drug pairs
by selecting the strongest inhibitors of kinases 1 and 2 alone, excluding their
common inhibitors, using the lowest Kd values (Davis et al., 2011) (Table S8).
The top co-essential kinase pairs predicted by the combinatorial KISS, as
well as the corresponding drug pairs of their individual inhibitors, were exper-
imentally tested in HCC1937 cells as described below.
Combinatorial Drug Synergy Testing
To test the combinatorial KISS predictions, the top-ranked drug combinations
in the HCC1937 cell line were tested in an 8 3 8 dose-matrix format covering
seven increasing concentrations of each drug, along with all their pairwise
combinations, as well as the negative control (0.1% DMSO, top left corner
of the 8 3 8 matrix) and the cell-killing positive control (100 mM benzethonium
chloride, bottom right corner of the matrix). Drugs were transferred in clear-
bottom black 384 well plates (Corning) using an Echo 550 Liquid Handler
(Labcyte) as per thematrix design. Liquid handling was performed using aMul-
tiDrop Combi dispenser (Thermo Scientific). 5 ml of culture medium was
dispensed in each well of pre-drugged plates to dissolve the drugs, and main-
tained in the orbital shaker for about 1 hr. Next, 20 ml of cell suspension (1,000
cells per 20 ml) was added to the drugged plates. After 72 hr of incubation at
37C in 5%CO2 in a humidified incubator, the cell viability wasmeasured using
CellTiter-Blue (Promega). 3 ml of CellTiter-Blue reagent was added to the
plates, which were then incubated for 2 hr at 37C. Fluorescence intensity1154 Chemistry & Biology 22, 1144–1155, August 20, 2015 ª2015 El(595 nm) was measured using a PheraStar FS plate reader (BMG Labtech).
The raw intensity values were converted to percent inhibition using the plate
average of positive and negative controls. Next, to reduce the dispensing-
related experimental variation from well to well, each row and column from
the 83 8matrices was fitted in GraphPad Prism software using logistic model,
and the two fitted values per well were then averaged. The expected combina-
tion effects were calculated on the basis of the Bliss independence model
(Bliss, 1956) (Table S9).
siRNA Combination Testing
The top co-essential kinase pairs predicted by the combinatorial KISS in
HCC1937 cells were tested in an siRNA combination assay. Three siRNAs
per kinase were purchased from Qiagen and tested in 43 4 matrices, in which
the top left corner was occupied by a control, and the remaining wells in the
first row and column by single siRNAs (at 8 nM) of the first and second kinase,
respectively. All the pairwise combinations were tested in the remaining nine
wells using 8 nM of each siRNA. SiRNAs were transferred to clear-bottom
384 well plates with the Echo 550 Liquid Handler. 5 ml of Opti-MEM (Life Tech-
nologies) containing 50 nl of Lipofectamine RNAiMAX Transfection Reagent
(Life Technologies) was added to each well of pre-siRNA-coated plates using
an MultiDrop Combi nl dispenser (Thermo Scientific) and incubated at room
temperature for 20 min on an orbital shaker. 20 ml of cell suspension (500 cells
per 20 ml) were seeded on the siRNA plate and the plates were maintained at
37C, in the presence of 5% CO2 in a humidified incubator for 96 hr. CellTiter-
Glo (Promega) reagent was then used to assess the viability of cells after siRNA
treatments. Z prime scores were calculated for each plate, and these remained
above 0.5, assuring good resolution. The fluorescence measurements were
converted to percent inhibition using the mean fluorescence of 16 positive
and 24 negative controls. The single siRNA knockdown effects were normal-
ized by taking the average of the inhibition values of single kinase knockdown
and those double kinase knockdown that included this kinase with lower inhi-
bition values, to make the single and double kinase knockdown results com-
parable. Maximum single siRNA knockdown effect was considered to be the
expected combinatorial effect in the absence of established synergy scoring
(see also Table S10).
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